Innovative drug R&D company SmartNuclide Biopharma raises nearly RMB100m in Series B

SmartNuclide Biopharma, a company which focuses on the research and development of innovative medicines in nuclear medicine, has announced the completion of nearly 100 million yuan in Series B financing round.
The investment was led by Ruihe Capital, with participation from Jiuyou Capital and other investment institutions.

SmartNuclide Biopharma, a company which focuses on the research and development of innovative medicines in nuclear medicine, has announced the completion of nearly 100 million yuan in Series B financing round.

The investment was led by Ruihe Capital, with participation from Jiuyou Capital and other investment institutions.

Proceeds from the fresh funding round will mainly be used to advance the progress of current research and development projects, including SNA001 clinical phase III trials and commercial production, SNA002 registration in China and the US, and SNA006 ’s First In Human trial, etc. At the same time, the company will independently establish a core platform for nuclear pharmaceuticals, enriching product development and expand cooperation with leading international R&D institutions.

Established in 2015, SmartNuclide Biopharma is a clinical-stage biopharmaceutical company focused on discovering and developing innovative biological drug products for molecular nuclear oncology, including both diagnostics and therapeutics. The company is committed to developing innovative pharmaceutical products in order to offer better treatment options to cancer patients.

Developer and researcher of biopharmaceuticals for molecular nuclear oncology. The company specializes in developing innovative biological drug products including both diagnostics and therapeutics formulations targeting molecular oncology, providing reliable and effective products for better cancer treatment.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/03/innovative-drug-r-d-company-smartnuclide-biopharma-raises-nearly-rmb100m-in-series-b/.

Leave a Reply

Please Login to Comment